Abstract
The development of nucleic acid assays is of critical clinical importance for the diagnosis of viral hepatitis and the management of antiviral therapy. For both chronic hepatitis B and C, sensitive and quantitative assays are required for the monitoring of viral load. Better assays are being developed and their role in the management of antiviral treatment has been clearly demonstrated. Genotyping assays are critical for the decision of treatment strategies in hepatitis C, although in hepatitis B this issue is more debated. The detection of viral genome mutations for the diagnosis of hepatitis B virus resistance is critical with the use of nucleoside analogs. This may also prove useful for anti-hepatitis C virus therapy with the rapid development of specific inhibitors that may select for drug-resistant mutants.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
